ESPE Abstracts

The purpose of the study was to study the effectiveness of the Liraglutide (Laraglan 18 mg/3 ml, Parla Pharmaceuticals, Azerbaijan) after 4 weeks of treatment in the obesity children over 12 years of age. For this purpose, 18 children were examined. 11 of those examined were girls (61%), 7 were boys (39%). The average age was 12.4±2.1 years. Initial average weight was 73.1±10.2 kg, BMI 30.6±5.6 kg/m2, height 152.5±12.4 cm. After 1 month, the weight was 71.0±8.4 kg, BMI 29.3±4.3 kg/m2, height 153.7±11.7 cm. Among the indicators, only the difference between BMI indicators was honest (P <0.05). Examinations the percentage of body components were conducted using the Body Composition Analyzer (Tanita corporation, Japan) in order to assess during obesity in children. During the examination, the fat mass was 28.6 ±4.2 kg, after 1 month 26.5±3.9 kg (P <0.002), liquid 42.1±5.2 kg, after 1 month 42.1±6.3 kg (P >0.05), fat-free mass 44.4±6.1 kg, after 1 month 44,5±5.9 kg (P >0.05), muscle mass was 32.6±6.1 kg, after 1 month 32.6±5.3 kg (P >0.05), bone mass was 2.27±0.9 kg, after 1 month 2.27±0.7 kg (P >0.05). Thus, Liraglutide (0.6 mg) and lifestyle therapy resulted in a significant reduction in BMI and fat mass after 4 weeks of treatment. Dangerous complications were not noted. The higher frequency of gastrointestinal side effects observed with Liraglutide suggests that this treatment may not be suitable for all patients.